Abstract: A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowing stream causing the mixing thereof, wherein the flow rate ratio of the anti-solvent: solvent is higher than 20:1, and collecting crystals that are generated.

Abstract: Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.

Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.

Abstract: The present invention relates to a hydrochloride salt of a peptide consisting of the sequence of CPAVKRDVDLFLT (SEQ ID NO: 1) as well as its combinations with other peptides for immunosuppressive purposes.

Abstract: The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.

Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.

Abstract: The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerization therapy.

Abstract: The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.

Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.

Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having Bermuda grass allergy and genetic sequences encoding same. These molecules are preferentially immunointeractive with T cells in subjects having a Bermuda grass pollen allergy. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterized by an aberrant, inappropriate or otherwise unwanted immune response to Bermuda grass pollen or derivative or homolog thereof.

Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.

Abstract: A first or second polypeptide for use in a method of treating or preventing a disorder by tolerization, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class II-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterized by an inappropriate immune response to the protein allergen from which the second polypeptide derives.

Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.

Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.

Abstract: The present invention relates to peptides which are formulated or engineered to prevent or reduce the formation of dimers.

Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.

Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.

Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferentially immunointeractive with T cells in subjects having an allergy to the Ara h 2 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterized by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 2 or derivative or homologue thereof.

Abstract: The present invention relates to peptides which are formulated or engineered to prevent or reduce the formation of dimers.

Abstract: The invention relates to a method of desensitising a patient to a polypeptide allergen the method comprising administering to the patient a peptide derived from the allergen wherein restriction to a MHC Class II molecule possessed by the patient can be demonstrated by the peptide and the peptide is able to induce a late phase response in an individual who possesses the said MHC Class II molecule. A composition comprising a plurality of peptides derived from a polypeptide allergen wherein for at least one of the peptides in the composition restriction to a MHC Class II molecule can be demonstrated, and the composition is able to induce a late phase response in an individual possessing the given MHC Class II moleculeis also provided. The invention also relates to a method of selecting a peptide for use as an immunotherapeutic agent for desensitising a patient to a polypeptide allergen capable of eliciting an allergic response in the patient.